1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Malaria - Drugs In Development, 2022, provides an overview of the Malaria (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. Treatment includes anti-malarial medicines and healthy lifestyle.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Malaria - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Malaria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Malaria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Malaria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 5, 13, 20, 58, 45 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 20, 40 and 37 molecules, respectively.
Malaria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Malaria (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Malaria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Malaria (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Malaria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Malaria (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Malaria (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Malaria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Malaria - Overview
- Malaria - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Malaria - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Malaria - Companies Involved in Therapeutics Development
- Malaria - Drug Profiles
- Malaria - Dormant Projects
- Malaria - Discontinued Products
- Malaria - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Malaria, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Malaria - Dormant Projects, 2022
- Malaria - Discontinued Products, 2022
- Number of Products under Development for Malaria, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 60 Degrees Pharmaceuticals LLC
- AbbVie Inc
- AchilleS Vaccines Srl
- Alfasigma SpA
- AliquantumRx Inc
- Allergy Therapeutics Plc
- Altimmune Inc
- Artemis Therapeutics Inc
- Artificial Cell Technologies Inc
- Atomwise Inc
- AUM LifeTech Inc
- Avalia Immunotherapies Ltd
- Bharat Biotech Ltd
- BioNTech SE
- Blue Water Vaccines Inc
- Brain-Gen LLC
- Bristol-Myers Squibb Co
- Carna Biosciences Inc
- Cascade Therapeutics Inc
- Cellics Therapeutics Inc
- Cesa Alliance SA
- Cilian AG
- Collaborations Pharmaceuticals Inc
- Crystec Ltd
- Curevac NV
- Curia Inc
- Daiichi Sankyo Co Ltd
- Eisai Co Ltd
- ElSohly Laboratories Inc
- EpicentRx Inc
- EpiVax Inc
- eTheRNA Immunotherapies NV
- Evotec SE
- Expres2ion Biotechnologies ApS
- Exscientia Plc
- GeoVax Labs Inc
- GSK plc
- Hawaii Biotech Inc
- Ibex Biosciences LLC
- Ichor Medical Systems Inc
- IGM Biosciences Inc
- Immune Modulation Inc
- Imutex Ltd
- IMV Inc
- Indoco Remedies Ltd
- Innovex Therapeutics SL
- IPCA Laboratories Ltd
- Jacobus Pharmaceutical Co Inc
- Johnson & Johnson
- Kainomyx Inc
- Kymab Ltd
- Luckwel Pharmaceuticals Inc
- Lumen Bioscience Inc
- Lyndra Therapeutics Inc.
- MedinCell SA
- MediSynergics LLC
- MegaNano BioTech Inc
- Merck & Co Inc
- Merck KGaA
- Microbiotix Inc
- Mitsubishi Tanabe Pharma Corp
- Modus Therapeutics AB
- Mycosynthetix Inc
- Mymetics Corp
- Nobelpharma Co Ltd
- Novartis AG
- Ocean Biomedical Inc
- Osivax SAS
- Otsuka Pharmaceutical Co Ltd
- Pacific Meniuoke Biopharmaceutical Company
- Pfizer Inc
- PGTx Ltd
- Protein Potential LLC
- Replikins Ltd
- Rodos BioTarget GmbH
- Sanaria Inc
- Sanofi
- Serum Institute of India Pvt Ltd
- Shin Poong Pharm Co Ltd
- Shionogi & Co Ltd
- Sumaya Biotech GmbH & Co KG
- Sumitomo Pharma Co Ltd
- Takeda Pharmaceutical Co Ltd
- Tandem Nano Ltd
- Tarsus Pharmaceuticals Inc
- Theravectys SA
- UCB SA
- Uvax Bio LLC
- Vac4All SAS
- VicuTec Biologicals GmbH
- VLP Biotech Inc
- VLP Therapeutics LLC
- Zydus Lifesciences Ltd
